Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-3/Melan-A Peptide-Pulsed PBMC + rhIL-12 in Metastatic Melanoma
NCT00002952Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jan 1997
- Primary completion
- Aug 2002
- Modality
- Cytokines & Interferons, Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MAGE-3 peptide-pulsed autologous peripheral blood mononuclear cells + Melan-A peptide-pulsed autologous peripheral blood mononuclear cells, recombinant interleukin-12 in melanoma, sponsored by University of Chicago. Started Jan 1997; status: completed.
02
Drugs
MAGE-3 peptide-pulsed autologous peripheral blood mononuclear cells + Melan-A peptide-pulsed autologous peripheral blood mononuclear cellsrecombinant interleukin-12
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00002952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002952.